Senseonics (SENS)

Executive Summary

Senseonics is a medical device company focused on long-term, implantable continuous glucose monitoring (CGM) systems for diabetes. Its flagship product, Eversense, offers a unique value proposition with a sensor that lasts up to 180 days (with a 365-day version in development), differentiating it from competitors like Dexcom and Abbott that offer shorter-duration transcutaneous sensors. The company has faced commercial challenges due to the need for a small surgical insertion procedure and intense competition. However, recent developments, including FDA approval for a 365-day sensor (expected in 2026) and potential expansion of Medicare coverage, could significantly improve adoption. Senseonics is also exploring partnerships to leverage its long-term sensor technology beyond diabetes, such as for other continuous analyte monitoring. Despite a depressed valuation following lower-than-expected sales, the upcoming catalysts could drive a re-rating if execution improves.

Upcoming Catalysts (preview)

• Q3 2026FDA approval and launch of 365-day Eversense sensor80% success
• Q4 2026Medicare coverage expansion for implantable CGM60% success
• Q2 2026New partnership or licensing deal for sensor platform50% success